Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The influenza A virus hemagglutinin protein H1 subtype is a trimeric glycoprotein found on the surface of the influenza A virion. It plays an essential role in viral infectivity by mediating two critical steps in the infection process. First, its globular head domain binds specifically to sialic acid-containing receptors on the surface of respiratory epithelial cells in humans and other hosts. This interaction determines both species specificity and tissue tropism. Second, after endocytosis into the host cell, exposure to acidic pH triggers a conformational change in hemagglutinin that drives fusion between the viral envelope and endosomal membrane—allowing release of viral RNA into the cytoplasm[2][4][7]. Hemagglutinin is also highly immunogenic; it is recognized by neutralizing antibodies that can block infection either by preventing receptor binding or inhibiting membrane fusion. The high variability of its head region underlies frequent antigenic drift—necessitating regular updates to seasonal flu vaccines—and occasional major shifts that can lead to pandemics such as those caused by H1N1 strains in 1918 and 2009[4]. The stem region is more conserved across subtypes; thus it has become a focus for universal flu vaccine development. As a primary mediator of entry into host cells—and because it elicits strong immune responses—hemaglutinnin remains one of the most important therapeutic targets for antiviral drugs (especially monoclonal antibodies) as well as vaccines against influenza A viruses[2][3][4].
Neutralizing antibodies block receptor binding or prevent conformational changes required for membrane fusion[2].
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza A virus hemagglutinin protein H1 subtype (HA (H1)).